Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.67 and traded as low as $0.50. Northwest Biotherapeutics shares last traded at $0.50, with a volume of 1,067,559 shares changing hands.
Northwest Biotherapeutics Stock Performance
The company has a market cap of $602.95 million, a PE ratio of -8.37 and a beta of -0.68. The stock has a fifty day moving average of $0.55 and a 200-day moving average of $0.67.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last released its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported ($0.02) EPS for the quarter. The firm had revenue of $0.45 million during the quarter.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- Consumer Discretionary Stocks Explained
- The Charles Schwab Company Can Hit New Highs
- What Does a Stock Split Mean?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
